Curasight

The presentation will include an update on the business progress made by the company during the first three quarters of 2023 and look ahead at the expected coming news flow. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer, besides the newly reported phase II data with uTRACE® in brain cancer and the preclinical data using uTREAT® in non-small cell lung cancer.

The HC Andersen Capital presentation will be webcasted live 13:30 - 14:00 (CET), Tuesday 28 November 2023.

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight’s website, after the presentation is completed.

For more information – please click here

The Stokk.io presentation will be webcasted live 14:00 - 14:30 (CET), Monday 27 November 2023.

Curasight will host a web conference about the Interim Report Q3 2023, via the platform Stokk.io and the Q&A is already open. Curasight has made this new solution available to make sure all interested can participate with their questions even though they may not be able to attend the event live. All answers in the recording and in a fully clickable transcript will be available afterwards. The web conference will be held in English.

For sign up and submit questions – please  click here